Form name	Number of respondents	Number of responses per respondent	Total responses	Average burden per response (hours)	Total burden hours
Project Narrative Update	1,325	1	1,325	4.00	5,300.00
Project Overview Form	500	1	500	1.00	500.00
Project Qualification Criteria	130	1	130	0.50	65.00
Project Work Plan	508	1	508	4.00	2,032.00
Proposal Cover Page	130	1	130	1.00	130.00
QIF Evaluative Measures Report	25	2	50	1.50	75.00
QIF Progress Report	25	12	300	1.50	450.00
QIF TJI Evaluative Measures Report	54	10	540	1.50	810.00
QIF TJI Progress Report	54	10	540	1.50	810.00
QIF Project Plan Form	100	1	100	1.00	100.00
Summary Page (New Access Point)	500	1	500	1.00	500.00
Summary Page (Service Area Competition)	360	1	360	0.50	180.00
LAL Cover page	110	1	110	0.50	55.00
Checklist for Adding a Transitional Care in a Carceral Setting Site to Scope	50	1	50	1.00	50.00
Checklist for Form 5A Scope Adjustments	1,875	1	1,875	0.50	937.50
Checklist for Form 5B Scope Adjustments	1,695	1	1,695	0.50	847.50
Total	28,588		30,350.00		32,785.55

Maria G. Button,

Director, Executive Secretariat.

[FR Doc. 2026–07793 Filed 4–21–26; 8:45 am]

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is giving notice of the invention listed below, which is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

FOR FURTHER INFORMATION CONTACT: Inquiries related to this licensing opportunity should be directed to: Brian Bailey at 240–669–5128, or *bbailey@mail.nih.gov.* Licensing information may be obtained by communicating with the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852: tel. 301–496–2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention.

SUPPLEMENTARY INFORMATION: Technology descriptions follows:

Neutralizing Monoclonal Antibodies Against West Nile Virus.

Description of Technology

West Nile virus (WNV) is a mosquito-borne flavivirus that can cause fever and, in some cases, severe neurologic disease. There is no approved human vaccine or specific antiviral treatment for WNV.

Researchers at NIAID's Vaccine Research Center (VRC), working with collaborators at Sheba Medical Center under the PREMISE program, identified five new human monoclonal antibodies that potently neutralize WNV. These antibodies bind the viral envelope (E) protein, with data indicating recognition of E dimers or quaternary epitopes on the virion.

The invention includes compositions comprising the antibodies alone or in combination, nucleic acids encoding them, vectors and host cells for production, and methods for preventing, treating, or detecting WNV infection. The antibodies may be formulated for therapeutic administration, including emergency-use settings, and may also support diagnostic and research applications.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration.

Potential Commercial Applications

- Prevention or treatment antibodies for WNV, including use alone or in combination.
- Antibodies that strongly target the WNV E protein.
- Potential treatments for WNV outbreak response and prevention in high-risk populations.
- Genetic and cell-engineering tools for antibody production and product development.
- Antibodies for WNV detection, surveillance, and research tests.
- Potential intravenous treatments for patients with WNV.

Competitive Advantages

- Shown to strongly neutralize WNV at low concentrations in laboratory cell-based studies.
- Novel antibodies with distinct molecular features not previously reported in scientific literature.
- Human monoclonal antibodies targeting E dimer or quaternary epitopes on the WNV virion.
- Potential applications in WNV treatment, diagnostics, and surveillance.
- Collaboration may help speed development to support WNV outbreak response.

Development Stage

- Pre-Clinical

Inventors: Dr. Daniel Douek, Dr. Chaim Schramm, Dr. Ananda Chowdhury, Dr. Parker Dabbs, Dr. Lu Wang, Dr. Sarah Smith, Dr. Leonid Serebryannyy, Dr. Theodore C. Pierson, Dr. Kimberly Dowd, Dr. Katherine Burgomaster, Dr. Laura Vanblargan, Dr. David Gordon, and Dr. Yuxiang Wang, all of NIAID; Dr. Yaniv Lustig, Dr. Yael

Ottolenghi, and Dr. Dror Harats, all of Sheba Medical Center.

Publications: n/a.

Intellectual Property: HHS Reference No. E–200–2024–0. U.S. Provisional Patent Application filed on July 31, 2024, and PCT Patent Application No. PCT/US2025/039922, filed on July 30, 2025.

Licensing Contact: To license this technology, please contact Brian Bailey at 240–669–5128, or *bbailey@mail.nih.gov,* and reference E–200–2024–0.

Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Brian Bailey at 240–669–5128, or *bbailey@mail.nih.gov.*

Dated: April 17, 2026.

Surekha Vathyam,

Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.

[FR Doc. 2026–07769 Filed 4–21–26; 8:45 am]

BILLING CODE 4167–05–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is giving notice of the invention listed below, which is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

FOR FURTHER INFORMATION CONTACT: Inquiries related to this licensing opportunity should be directed to: Brian Bailey at 240–669–5128, or *bbailey@mail.nih.gov.* Licensing information may be obtained by communicating with the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852: tel. 301–496–2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention.

SUPPLEMENTARY INFORMATION: Technology description follows:

Neutralizing Antibodies Against West Nile Virus

Description of Technology:

West Nile virus (WNV) is a mosquito-borne virus that can cause severe disease affecting the brain and nervous system, especially in older adults and people with weakened immune systems. There is no approved human vaccine or specific antiviral treatment for WNV.

Researchers at NIAID's Vaccine Research Center (VRC), together with collaborators at Sheba Medical Center and the Israeli Ministry of Health, have identified and characterized seven new fully human monoclonal antibodies that bind to the WNV envelope (E) protein—the main surface protein the virus uses to enter cells. In laboratory studies, these antibodies (AIS–196, AIS–204, AIS–259, AIS–260, AIS–261, AIS–262, and AIS–265) strongly blocked WNV infection, and several also showed protective effects in a mouse model.

The invention includes the antibody sequences and tools needed to produce them, supporting development of full-length antibody therapies or smaller antibody fragments. These antibodies could help prevent WNV disease in people at higher risk or treat infection early, either individually or in combination. Modified versions are also included that may extend how long the antibodies remain active in the body or adjust how they interact with the immune system. The antibodies may also be useful in laboratory tests for WNV diagnosis, surveillance, and research.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration.

Potential Commercial Applications:

- Prevention or treatment antibodies for WNV, especially for people at higher risk of severe disease or after a known exposure.
- Fully human antibodies that strongly neutralize virus infection by targeting its key surface E protein.
- Flexible formats for different uses, including full-length antibodies or antibody fragments, and the option to use a single antibody or a combination (''cocktail'').
- Engineered versions designed to last longer in the body and tune immune functions for safety and performance.
- High-quality antibodies for WNV testing and surveillance, supporting laboratory detection, public health monitoring, and research.
- Neutralizing antibodies as components of delivery systems for prophylactic or therapeutic applications.

Competitive Advantages:

- An antibody-based approach for WNV prevention or treatment, given the lack of an approved human vaccine, specific antiviral treatment, or licensed antibody therapy.
- Strong virus-neutralizing activity.
- Fully human antibodies, which are less likely to cause anti-drug immune responses than non-human or humanized antibodies.
- Engineered versions that may last longer in the body and tune immune activity to improve safety and effectiveness.
- High-quality antibodies that support WNV prevention or treatment and can also be used in diagnostic tests, public health surveillance, and research.

Development Stage:

- Pre-Clinical

Inventors: Dr. Theodore Pierson, Dr. Kimberly Dowd, and Dr. Daniel Douek, all of NIAID; Dr. Dror Harats, Dr. Yael Ottolenghi, and Dr. Gili Regev-Yochay, all of Sheba Impact Ltd.; Dr. Yaniv Lustig, of Sheba Impact Ltd. and Ministry of Health, State of Israel.

Intellectual Property: HHS Reference No. E–021–2026–0. Provisional Patent Application No. 63/991,485, filed on February 26, 2026.

Licensing Contact: To license this technology, please contact Brian Bailey at 240–669–5128, or *bbailey@mail.nih.gov,* and reference E–021–2026–0.

Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Brian Bailey at 240–669–5128, or *bbailey@mail.nih.gov.*

Dated: April 17, 2026.

Surekha Vathyam,

Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.

[FR Doc. 2026–07770 Filed 4–21–26; 8:45 am]

BILLING CODE 4167–05–P